BioPharma Resources

Drug Trial Radar · NCT07435428

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled and Open-label Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants, and to Evaluate the Long-term Efficacy and Safety of Repeat Doses of IPN10200 in the Same Indication

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,305 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,305

Actual

Start

Feb 18, 2026

Primary completion

Sep 28, 2026

Study completion Sep 11, 2028

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness and safety of a single dose of Corabotase (also known as IPN10200) compared to placebo (double-blind phase) and how well and safely repeat doses of Corabotase work over time (open-label phase) in adult participants with moderate to severe glabellar lines. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. All participants in the double-blind phase will receive Corabotase or placebo during the first treatment cycle. De novo participants in the open-label phase will receive IPN10200 during the first treatment cycle. Some participants may receive additional treatment cycles with Corabotase depending on their eligibility. There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period where participants may receive up to 4 treatment cycles. In the double-blind phase, participants receive a single treatment of Corabotase or placebo. In the open-label phase (rollover participants from double-blind), eligible participants may receive additional cycles of Corabotase . In the open-label phase (de novo participants), participants will receive Corabotase in the first cycle and eligible participants may receive additional cycles of Corabotase. Requires multiple visits during the first month followed by 1 visit every month. * A follow-up period (24 weeks) after the last injection where participants' health will be monitored. Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 107 weeks. Participants may withdraw consent to participate at any time.

Conditions

  • Moderate to Severe Glabellar Lines

Interventions

  • CorabotaseBiological

    A single vial of lyophilised powder for solution for injection will be injected locally into several sites across the glabellar region.

  • PlaceboBiological

    A single vial of lyophilised powder for solution, containing excipients without active substance, will be injected locally into several sites across the glabellar region.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For North America: Percentage of participants responding to treatmentTime frame: At week 4
  2. For EU and ROW: Percentage of participants responding to treatment as measured by ≥2-grades improvement on the ILA at maximum frownTime frame: From baseline to week 4

Locations

60 sites in 4 countries. Site status is shown where the registry gives one.

  • Rivkin Westside Aesthetics

    Los Angeles, California

  • Clinical Testing of Beverly Hills

    Los Angeles, California

  • Eye Research Foundation

    Newport Beach, California

  • Steve Yoelin MD Medical Associates Inc

    Newport Beach, California

  • Skin and Beauty Center

    Pasadena, California

  • Dermatology Cosmetic Laser Medical Associates of La Jolla Inc.

    San Diego, California

  • Southern California Dermatology, Inc.

    Santa Ana, California

  • DMR Research, PLLC

    Westport, Connecticut

  • Center for Dermatology and Dermatologic Surgery

    Washington D.C., District of Columbia

  • Skin and Cancer Associates (SCA) and the Center for Cosmetic Enhancement (CCE) - Aventura

    Aventura, Florida

  • Weinkle Dermatology

    Bradenton, Florida

  • Skin Research Institute

    Coral Gables, Florida

  • Miami Dermatology & Laser Research

    Miami, Florida

  • Kavali Plastic Surgery and Skin Renewal Center

    Atlanta, Georgia

  • DeNova Research

    Chicago, Illinois

  • Chicago Cosmetic and Dermatologic Research

    Chicago, Illinois

  • Advanced Dermatology, A Forefront Dermatology Practice

    Lincolnshire, Illinois

  • LASSI - Laser and Skin Surgery Center of Indiana

    Indianapolis, Indiana

  • Coleman Center For Cosmetic Dermatologic Surgery

    Metairie, Louisiana

  • DelRicht Research

    New Orleans, Louisiana

  • Etre, Cosmetic Dermatology and Laser Center

    New Orleans, Louisiana

  • Maryland Laser, Skin, & Vein Institute, LLC (MDLSV)

    Hunt Valley, Maryland

  • Lawrence J. Green, MD. LLC

    Rockville, Maryland

  • SkinCare Physicians

    Chestnut Hill, Massachusetts

  • Michigan Center for Research Company

    Clarkston, Michigan

  • Skin Specialists PC dba Schlessinger MD

    Omaha, Nebraska

  • StracSkin

    Portsmouth, New Hampshire

  • Rejuva Center at Williams

    Latham, New York

  • The Center for Dermatology, Cosmetic & Laser Surgery

    Mount Kisco, New York

  • Luxurgery

    New York, New York

  • Dr. Z. Paul Lorenc MD, Office Of

    New York, New York

  • Skin Search Of Rochester, Inc.

    Rochester, New York

  • Rochester Dermatologic Surgery, P.C.

    Victor, New York

  • Aesthetic Solutions P.A.

    Chapel Hill, North Carolina

  • Dermatology, Laser & Vein Specialists of the Carolinas (DLVSC) - Charlotte Office

    Charlotte, North Carolina

  • Nash Research Group, LLC

    Powell, Ohio

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Paddington Testing Company

    Philadelphia, Pennsylvania

  • Brian S. Biesman MD, PLLC

    Nashville, Tennessee

  • Tennessee Clinical Research Center

    Nashville, Tennessee

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.